Research programme: haemophilia A gene therapies - Symvivo
Alternative Names: bacTRL-FVIIILatest Information Update: 29 Oct 2020
At a glance
- Originator Symvivo
- Class Antihaemorrhagics; Bifidobacteria; Blood coagulation factors; Gene therapies
- Mechanism of Action Bacteria replacements; Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haemophilia A
Most Recent Events
- 26 Oct 2020 Research programme: haemophilia A gene therapies - Symvivo is available for licensing as of 26 Oct 2020. https://www.symvivo.com/contact
- 26 Oct 2020 Preclinical trials in Haemophilia A in Canada (IV) before October 2020 (Symvivo pipeline, October 2020)